Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
NCT05366829Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Rutgers University. Primary endpoints: Progression-Free Survival at 1 year and Adverse Events at 48 months. Started Jul 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05366829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366829.